0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Company Overview: Medifast, Inc. (NYSE: MED) is a global health and wellness company that manufactures and distributes nutritional products and plans to assist people in losing weight, maintaining weight, and leading a healthy lifestyle. It operates in the United States and Asia Pacific (Hong Kong and Singapore) through its community, OPTAVIA, where its coaches teach the art of developing holistic, healthy habits through its signature "Habits of Health" Transformational System.
MED Details
Key Takeaways from FY21 (ended December 31, 2021)
Revenues & Operating Profit Key Highlights; Analysis by Kalkine Group
Recent Developments
Other Key Findings in FY21
Balance Sheet & Liquidity Position
Key Metrics: In FY21, MED's operating and net margins were 14.2% and 10.7%, compared to the industry median of 13.5% and 7.7%, respectively. ROE stood at 91.2%, 7,540 bps more than the industry median.
Profitability Metrics; Analysis by Kalkine Group
Top 10 Shareholders: The top 10 shareholders together form around 52.12% of the total shareholding, while the top 4 constitute the maximum holding. BlackRock Institutional Trust Co., N.A. and The Vanguard Group, Inc., hold the maximum stake in the company at 15.17% and 12.99%, respectively, as also highlighted in the chart below:
Top 10 Shareholders; Analysis by Kalkine Group
Risk Analysis
Outlook
Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuation (Illustrative)
Source: Analysis by Kalkine Group
*% Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation: Over the past nine months, MED's share price has corrected 39.95%. The stock is currently leaning towards the lower end of its 52-week range of USD 161.44 to USD 336.99. We have valued the stock using the Price/Earnings multiple-based illustrative relative valuation method and arrived at a target price with an upside of mid-twenties (in percentage terms). We believe that the company is trading at premium with its peer's average, considering itsdebt free balance sheet, consistency in terms of margin reported over last five years , strong profitability, increasing demand for its products, etc. We have taken peers like NU Skin Enterprises, Inc. (NYSE: NUS) and Edgewell Personal Care Company (NYSE: EPC). Considering the strong topline performance, solid dividend yield, robust balance sheet, positive outlook, associated risks, and current valuation, we give a "Buy" recommendation on the stock at the closing price of USD 169.44, up 3.58% as of March 15, 2022.
MED Technical Chart, Data Source: REFINITIV
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decision should be made depending on the investors' appetite for upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above.
Technical Indicators Defined
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and the uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.